Nasdaq stocks posting largest percentage decreases
AP - Tue Apr 01, 5:03PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at the close of trading:
NephroGenex, Inc. Reports Year-End 2013 Financial Results
GlobeNewswire - Mon Mar 31, 7:16AM CDT
-- Raised over $37 million in gross proceeds during Feb. 2014 Initial Public Offering
NephroGenex Announces Research Collaborations for Pivotal Studies of Pyridorin(TM) in Diabetic Nephropathy
GlobeNewswire - Thu Mar 27, 7:14AM CDT
NephroGenex, Inc.(Nasdaq:NRX), a pharmaceutical company focused on the development of therapeutics to treat kidney disease, today announced collaborations with two leading research organizations to conduct the Company's Phase 3 PIONEER (PyrIdOriN in DiabEtic NEphRopathy) study.
NephroGenex Announces Closing of Initial Public Offering
GlobeNewswire - Fri Feb 14, 10:30AM CST
NephroGenex, Inc. (Nasdaq:NRX), a pharmaceutical company focused on the development of therapeutics to treat kidney disease, today announced the closing of its initial public offering of 3,100,000 shares of common stock at a public offering price of $12.00 per share for total gross proceeds of $37,200,000 before underwriting discounts. In addition, NephroGenex has granted the underwriter a 45-day option to purchase up to an additional 465,000 shares of common stock from NephroGenex to cover over-allotments, if any.
NASDAQ Welcomes NephroGenex (NASDAQ:NRX) to The NASDAQ Stock Market
GlobeNewswire - Tue Feb 11, 11:24AM CST
The NASDAQ OMX Group, Inc. (Nasdaq:NDAQ) announced that trading of NephroGenex (Nasdaq:NRX), a drug development company focusing on kidney disease, commenced on The NASDAQ Stock Market on February 11, 2014.
NephroGenex Prices Initial Public Offering of Common Stock
GlobeNewswire - Mon Feb 10, 5:49PM CST
NephroGenex, Inc. (Nasdaq:NRX), a pharmaceutical company focused on the development of therapeutics to treat kidney disease, today announced the pricing of its initial public offering of 3,100,000 shares of its common stock at an initial public offering price of $12.00 per share. The gross proceeds to NephroGenex is expected to be $37,200,000 before underwriting discounts and commissions and other offering expenses. All of the common stock is being offered by NephroGenex. In addition, NephroGenex has granted the underwriters a 45-day option to purchase up to an additional 465,000 shares of common stock from NephroGenex to cover over-allotments, if any. NephroGenex's common stock has been approved for listing on the NASDAQ Capital Market and is expected to begin trading under the ticker symbol "NRX" on February 11, 2014.